Patient Engagement Solutions Market Size & Share Analysis - Emerging Trends, Growth Opportunities, Competitive Landscape, and Forecasts (2025

Description

The global patient engagement solutions market was valued at USD 20.3 billion in 2024 and is projected to reach USD 45.0 billion by 2032, growing at a compound annual growth rate (CAGR) of 10.6% during the forecast period from 2025 to 2032. The market's growth is primarily driven by the rising prevalence of chronic diseases, the increasing demand for advanced healthcare solutions, and improvements in healthcare infrastructure. The increasing adoption of wearable health technology, a growing geriatric population, and the expanded use of mobile health solutions are further contributing to the market's expansion.

Patient engagement involves encouraging individuals to actively manage their well-being, which leads to improved fitness outcomes and reduced healthcare costs. As healthcare facilities seek to optimize their operations, automated solutions such as interactive voice response systems have been adopted to help reduce call volumes, improve patient interactions, and lower hospital readmission rates. These advancements are encouraging the development of more sophisticated patient engagement tools, thereby increasing market growth.

Key Insights

The software category is the largest and fastest-growing segment, holding an 80% market share in 2024. Standalone software solutions deliver specialized features, while integrated solutions provide a more comprehensive approach to real-time monitoring, data sharing, and patient-provider communication. The shift toward integrated software has improved operational efficiency in healthcare facilities.

On-premises solutions held a dominant share of 75% in 2024, driven by the need for healthcare institutions to maintain control over their data and infrastructure. However, cloud-based solutions, offering greater flexibility and security, are expected to grow at the highest CAGR.

The health management category accounted for 70% of the market share in 2024. These solutions focus on chronic condition management, medication adherence, and wellness enhancement, driving broad adoption across healthcare settings.

Chronic diseases, particularly cardiovascular diseases and diabetes, remain the largest therapeutic area in patient engagement, making up 65% of the market share in 2024. However, mental health is the fastest-growing therapeutic area, fueled by rising awareness and the growing demand for digital therapy and mood tracking tools.

North America holds the largest share of the market at over 40%, with the U.S. leading due to its well-established healthcare infrastructure, growing healthcare expenditure, and rising chronic disease prevalence. The U.S. is also experiencing a shift toward patient engagement solutions to streamline healthcare management and improve patient outcomes.

The increasing demand for wearable healthcare devices is significantly driving the market. Wearables that track vital signs such as blood pressure, blood sugar, and body mass index are increasingly popular for both remote monitoring and disease management. These devices help in personalized diagnosis and reduce the need for hospital visits, thus lowering overall healthcare costs.

The rise in healthcare costs globally is another key driver for market growth. As healthcare expenses continue to rise, solutions that help reduce hospital readmissions and improve patient compliance with treatment plans are gaining popularity.

The adoption of patient engagement solutions is also being driven by government organizations that aim to promote disease prevention and chronic disease management. This trend is supporting the market's growth, especially in both developed and emerging markets.

The market is fragmented, with a range of players from large healthcare corporations to startups offering specialized software, mobile applications, and wearable devices. Regulatory requirements like HIPAA and GDPR further contribute to the diversity of the market, as solutions must be customized to meet the specific needs of various regions.

Key companies driving the patient engagement solutions market include McKesson Corporation, Cerner Corporation, Epic Systems Corporation, Orion Health, and Allscripts Healthcare LLC. These players are continually innovating their offerings to meet the evolving needs of healthcare providers and patients.

Product Code: 10542

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market Size Breakdown, by Component
- 1.4.2. Market Size Breakdown, by Delivery Mode
- 1.4.3. Market Size Breakdown, by Application
- 1.4.4. Market Size Breakdown, by Therapeutic Area
- 1.4.5. Market Size Breakdown, by End User
- 1.4.6. Market Size Breakdown, by Region
1.5. Market Data Reporting Unit
- 1.5.1. Revenue
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence Database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Industry Background
5.2. Market Dynamics
- 5.2.1. Trends
- 5.2.2. Drivers
- 5.2.3. Restraints/Challenges
- 5.2.4. Emerging Economies and Key Opportunities
- 5.2.5. Impact Analysis of Drivers/Restraints
5.3. Impact of COVID-19
5.4. Sociopolitical Impact
5.5. Porter's Five Forces Analysis
- 5.5.1. Bargaining Power of Buyers
- 5.5.2. Bargaining Power of Suppliers
- 5.5.3. Threat of New Entrants
- 5.5.4. Intensity of Rivalry
- 5.5.5. Threat of Substitutes
5.6. Innovation and Technology Trends
5.7. Economic and Regulatory Impact
5.8. Market Entry Strategies

Chapter 6. Competitive Landscape

6.1. List of Market Players and their Offerings
6.2. Market Share of Key Players (2024)
- 6.2.1. Global
- 6.2.2. North America
- 6.2.3. Europe
- 6.2.4. Asia-Pacific
- 6.2.5. Latin America
- 6.2.6. Middle East & Africa
6.3. Competitive Benchmarking of Key Players
6.4. Recent Strategic Developments by Key Players
6.5. Company Leadership Matrix

Chapter 7. Global Market

7.1. Overview
7.2. Market Revenue, by Component (2019-2032)
7.3. Market Revenue, by Delivery Mode (2019-2032)
7.4. Market Revenue, by Application (2019-2032)
7.5. Market Revenue, by Therapeutic Area (2019-2032)
7.6. Market Revenue, by End User (2019-2032)
7.7. Market Revenue, by Region (2019-2032)

Chapter 8. North America Market

8.1. Overview
8.2. Market Revenue, by Component (2019-2032)
8.3. Market Revenue, by Delivery Mode (2019-2032)
8.4. Market Revenue, by Application (2019-2032)
8.5. Market Revenue, by Therapeutic Area (2019-2032)
8.6. Market Revenue, by End User (2019-2032)
8.7. Market Revenue, by Country (2019-2032)

Chapter 9. Europe Market

9.1. Overview
9.2. Market Revenue, by Component (2019-2032)
9.3. Market Revenue, by Delivery Mode (2019-2032)
9.4. Market Revenue, by Application (2019-2032)
9.5. Market Revenue, by Therapeutic Area (2019-2032)
9.6. Market Revenue, by End User (2019-2032)
9.7. Market Revenue, by Country (2019-2032)

Chapter 10. Asia-Pacific Market

10.1. Overview
10.2. Market Revenue, by Component (2019-2032)
10.3. Market Revenue, by Delivery Mode (2019-2032)
10.4. Market Revenue, by Application (2019-2032)
10.5. Market Revenue, by Therapeutic Area (2019-2032)
10.6. Market Revenue, by End User (2019-2032)
10.7. Market Revenue, by Country (2019-2032)

Chapter 11. Latin America Market

11.1. Overview
11.2. Market Revenue, by Component (2019-2032)
11.3. Market Revenue, by Delivery Mode (2019-2032)
11.4. Market Revenue, by Application (2019-2032)
11.5. Market Revenue, by Therapeutic Area (2019-2032)
11.6. Market Revenue, by End User (2019-2032)
11.7. Market Revenue, by Country (2019-2032)

Chapter 12. Middle East & Africa Market

12.1. Overview
12.2. Market Revenue, by Component (2019-2032)
12.3. Market Revenue, by Delivery Mode (2019-2032)
12.4. Market Revenue, by Application (2019-2032)
12.5. Market Revenue, by Therapeutic Area (2019-2032)
12.6. Market Revenue, by End User (2019-2032)
12.7. Market Revenue, by Country (2019-2032)

Chapter 13. U.S. Market

13.1. Overview
13.2. Economic Indicators
13.3. Demographics and Population Insights
13.4. Regional Hotspots
13.5. Growth Drivers
13.6. Challenges and Barriers
13.7. Competitive Strategies
13.8. Emerging Players
13.9. Compliance Requirements
13.10. Emerging Investment Areas
13.11. Major Ongoing Projects
13.12. Market Size and Forecast
- 13.12.1. Market Revenue, by Component (2019-2032)
- 13.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 13.12.3. Market Revenue, by Application (2019-2032)
- 13.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 13.12.5. Market Revenue, by End User (2019-2032)

Chapter 14. Canada Market

14.1. Overview
14.2. Economic Indicators
14.3. Demographics and Population Insights
14.4. Regional Hotspots
14.5. Growth Drivers
14.6. Challenges and Barriers
14.7. Competitive Strategies
14.8. Emerging Players
14.9. Compliance Requirements
14.10. Emerging Investment Areas
14.11. Major Ongoing Projects
14.12. Market Size and Forecast
- 14.12.1. Market Revenue, by Component (2019-2032)
- 14.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 14.12.3. Market Revenue, by Application (2019-2032)
- 14.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 14.12.5. Market Revenue, by End User (2019-2032)

Chapter 15. U.K. Market

15.1. Overview
15.2. Economic Indicators
15.3. Demographics and Population Insights
15.4. Regional Hotspots
15.5. Growth Drivers
15.6. Challenges and Barriers
15.7. Competitive Strategies
15.8. Emerging Players
15.9. Compliance Requirements
15.10. Emerging Investment Areas
15.11. Major Ongoing Projects
15.12. Market Size and Forecast
- 15.12.1. Market Revenue, by Component (2019-2032)
- 15.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 15.12.3. Market Revenue, by Application (2019-2032)
- 15.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 15.12.5. Market Revenue, by End User (2019-2032)

Chapter 16. Germany Market

16.1. Overview
16.2. Economic Indicators
16.3. Demographics and Population Insights
16.4. Regional Hotspots
16.5. Growth Drivers
16.6. Challenges and Barriers
16.7. Competitive Strategies
16.8. Emerging Players
16.9. Compliance Requirements
16.10. Emerging Investment Areas
16.11. Major Ongoing Projects
16.12. Market Size and Forecast
- 16.12.1. Market Revenue, by Component (2019-2032)
- 16.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 16.12.3. Market Revenue, by Application (2019-2032)
- 16.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 16.12.5. Market Revenue, by End User (2019-2032)

Chapter 17. France Market

17.1. Overview
17.2. Economic Indicators
17.3. Demographics and Population Insights
17.4. Regional Hotspots
17.5. Growth Drivers
17.6. Challenges and Barriers
17.7. Competitive Strategies
17.8. Emerging Players
17.9. Compliance Requirements
17.10. Emerging Investment Areas
17.11. Major Ongoing Projects
17.12. Market Size and Forecast
- 17.12.1. Market Revenue, by Component (2019-2032)
- 17.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 17.12.3. Market Revenue, by Application (2019-2032)
- 17.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 17.12.5. Market Revenue, by End User (2019-2032)

Chapter 18. Italy Market

18.1. Overview
18.2. Economic Indicators
18.3. Demographics and Population Insights
18.4. Regional Hotspots
18.5. Growth Drivers
18.6. Challenges and Barriers
18.7. Competitive Strategies
18.8. Emerging Players
18.9. Compliance Requirements
18.10. Emerging Investment Areas
18.11. Major Ongoing Projects
18.12. Market Size and Forecast
- 18.12.1. Market Revenue, by Component (2019-2032)
- 18.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 18.12.3. Market Revenue, by Application (2019-2032)
- 18.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 18.12.5. Market Revenue, by End User (2019-2032)

Chapter 19. Spain Market

19.1. Overview
19.2. Economic Indicators
19.3. Demographics and Population Insights
19.4. Regional Hotspots
19.5. Growth Drivers
19.6. Challenges and Barriers
19.7. Competitive Strategies
19.8. Emerging Players
19.9. Compliance Requirements
19.10. Emerging Investment Areas
19.11. Major Ongoing Projects
19.12. Market Size and Forecast
- 19.12.1. Market Revenue, by Component (2019-2032)
- 19.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 19.12.3. Market Revenue, by Application (2019-2032)
- 19.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 19.12.5. Market Revenue, by End User (2019-2032)

Chapter 20. China Market

20.1. Overview
20.2. Economic Indicators
20.3. Demographics and Population Insights
20.4. Regional Hotspots
20.5. Growth Drivers
20.6. Challenges and Barriers
20.7. Competitive Strategies
20.8. Emerging Players
20.9. Compliance Requirements
20.10. Emerging Investment Areas
20.11. Major Ongoing Projects
20.12. Market Size and Forecast
- 20.12.1. Market Revenue, by Component (2019-2032)
- 20.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 20.12.3. Market Revenue, by Application (2019-2032)
- 20.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 20.12.5. Market Revenue, by End User (2019-2032)

Chapter 21. Japan Market

21.1. Overview
21.2. Economic Indicators
21.3. Demographics and Population Insights
21.4. Regional Hotspots
21.5. Growth Drivers
21.6. Challenges and Barriers
21.7. Competitive Strategies
21.8. Emerging Players
21.9. Compliance Requirements
21.10. Emerging Investment Areas
21.11. Major Ongoing Projects
21.12. Market Size and Forecast
- 21.12.1. Market Revenue, by Component (2019-2032)
- 21.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 21.12.3. Market Revenue, by Application (2019-2032)
- 21.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 21.12.5. Market Revenue, by End User (2019-2032)

Chapter 22. Australia Market

22.1. Overview
22.2. Economic Indicators
22.3. Demographics and Population Insights
22.4. Regional Hotspots
22.5. Growth Drivers
22.6. Challenges and Barriers
22.7. Competitive Strategies
22.8. Emerging Players
22.9. Compliance Requirements
22.10. Emerging Investment Areas
22.11. Major Ongoing Projects
22.12. Market Size and Forecast
- 22.12.1. Market Revenue, by Component (2019-2032)
- 22.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 22.12.3. Market Revenue, by Application (2019-2032)
- 22.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 22.12.5. Market Revenue, by End User (2019-2032)

Chapter 23. India Market

23.1. Overview
23.2. Economic Indicators
23.3. Demographics and Population Insights
23.4. Regional Hotspots
23.5. Growth Drivers
23.6. Challenges and Barriers
23.7. Competitive Strategies
23.8. Emerging Players
23.9. Compliance Requirements
23.10. Emerging Investment Areas
23.11. Major Ongoing Projects
23.12. Market Size and Forecast
- 23.12.1. Market Revenue, by Component (2019-2032)
- 23.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 23.12.3. Market Revenue, by Application (2019-2032)
- 23.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 23.12.5. Market Revenue, by End User (2019-2032)

Chapter 24. South Korea Market

24.1. Overview
24.2. Economic Indicators
24.3. Demographics and Population Insights
24.4. Regional Hotspots
24.5. Growth Drivers
24.6. Challenges and Barriers
24.7. Competitive Strategies
24.8. Emerging Players
24.9. Compliance Requirements
24.10. Emerging Investment Areas
24.11. Major Ongoing Projects
24.12. Market Size and Forecast
- 24.12.1. Market Revenue, by Component (2019-2032)
- 24.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 24.12.3. Market Revenue, by Application (2019-2032)
- 24.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 24.12.5. Market Revenue, by End User (2019-2032)

Chapter 25. Brazil Market

25.1. Overview
25.2. Economic Indicators
25.3. Demographics and Population Insights
25.4. Regional Hotspots
25.5. Growth Drivers
25.6. Challenges and Barriers
25.7. Competitive Strategies
25.8. Emerging Players
25.9. Compliance Requirements
25.10. Emerging Investment Areas
25.11. Major Ongoing Projects
25.12. Market Size and Forecast
- 25.12.1. Market Revenue, by Component (2019-2032)
- 25.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 25.12.3. Market Revenue, by Application (2019-2032)
- 25.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 25.12.5. Market Revenue, by End User (2019-2032)

Chapter 26. Mexico Market

26.1. Overview
26.2. Economic Indicators
26.3. Demographics and Population Insights
26.4. Regional Hotspots
26.5. Growth Drivers
26.6. Challenges and Barriers
26.7. Competitive Strategies
26.8. Emerging Players
26.9. Compliance Requirements
26.10. Emerging Investment Areas
26.11. Major Ongoing Projects
26.12. Market Size and Forecast
- 26.12.1. Market Revenue, by Component (2019-2032)
- 26.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 26.12.3. Market Revenue, by Application (2019-2032)
- 26.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 26.12.5. Market Revenue, by End User (2019-2032)

Chapter 27. U.A.E. Market

27.1. Overview
27.2. Economic Indicators
27.3. Demographics and Population Insights
27.4. Regional Hotspots
27.5. Growth Drivers
27.6. Challenges and Barriers
27.7. Competitive Strategies
27.8. Emerging Players
27.9. Compliance Requirements
27.10. Emerging Investment Areas
27.11. Major Ongoing Projects
27.12. Market Size and Forecast
- 27.12.1. Market Revenue, by Component (2019-2032)
- 27.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 27.12.3. Market Revenue, by Application (2019-2032)
- 27.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 27.12.5. Market Revenue, by End User (2019-2032)

Chapter 28. Saudi Arabia Market

28.1. Overview
28.2. Economic Indicators
28.3. Demographics and Population Insights
28.4. Regional Hotspots
28.5. Growth Drivers
28.6. Challenges and Barriers
28.7. Competitive Strategies
28.8. Emerging Players
28.9. Compliance Requirements
28.10. Emerging Investment Areas
28.11. Major Ongoing Projects
28.12. Market Size and Forecast
- 28.12.1. Market Revenue, by Component (2019-2032)
- 28.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 28.12.3. Market Revenue, by Application (2019-2032)
- 28.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 28.12.5. Market Revenue, by End User (2019-2032)

Chapter 29. South Africa Market

29.1. Overview
29.2. Economic Indicators
29.3. Demographics and Population Insights
29.4. Regional Hotspots
29.5. Growth Drivers
29.6. Challenges and Barriers
29.7. Competitive Strategies
29.8. Emerging Players
29.9. Compliance Requirements
29.10. Emerging Investment Areas
29.11. Major Ongoing Projects
29.12. Market Size and Forecast
- 29.12.1. Market Revenue, by Component (2019-2032)
- 29.12.2. Market Revenue, by Delivery Mode (2019-2032)
- 29.12.3. Market Revenue, by Application (2019-2032)
- 29.12.4. Market Revenue, by Therapeutic Area (2019-2032)
- 29.12.5. Market Revenue, by End User (2019-2032)

Chapter 30. Company Profiles

Chapter 31. Appendix

31.1. Sources and References
31.2. Related Reports

Patient Engagement Solutions Market Size & Share Analysis - Emerging Trends, Growth Opportunities, Competitive Landscape, and Forecasts (2025 - 2032)